//fpnotebook.com/
Abacavir
Aka: Abacavir, Ziagen
- See Also
- Anti-Retroviral Therapy
- Nucleoside Reverse Transcriptase Inhibitor
- Contraindications
- HLA-B*5701 positive state (screen in advance of starting)
- Associated with life-threatening Hypersensitivity
- Mechanism
- Nucleoside Reverse Transcriptase Inhibitor
- Dosing
- Abacavir 300 mg PO bid
- Precautions
- Do not use unless patient is negative for HLA-B5701
- Risk of Hypersensitivity Reaction if HLA-B5701 positive
- Lucas (2007) J Antimicrob Chemother 59(4):591-3 +PMID:17317695 [PubMed]
- Adverse Effects
- Hypersensitivity (3%)
- Presents with Fever and Rash
- Associated with HLA-B*5701 positive state
- Mean onset 11 days after start
- Lethal reaction if restarted after reaction (50%)
- Never rechallenge Abacavir after reaction
- Cardiovascular risk
- Unclear association is being investigated
- Resources: Abacavir Hypersensitivity Registry
- Phone: 1-800-270-0425
- References
- (1998) Med Lett Drugs Ther 40(1041):115 [PubMed]
- (2009) Treat Guidel Med Lett 7(78): 11-22 [PubMed]
- Reust (2011) Am Fam Physician 83(12): 1443-51 [PubMed]